Liquidia Co. (NASDAQ:LQDA) CFO Michael Kaseta Sells 23,370 Shares

Liquidia Co. (NASDAQ:LQDA) CFO Michael Kaseta sold 23,370 shares of the business’s stock in a transaction on Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total transaction of $275,298.60. Following the transaction, the chief financial officer now owns 401,755 shares in the company, valued at $4,732,673.90. The trade was a 5.50 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Michael Kaseta also recently made the following trade(s):

• On Monday, December 2nd, Michael Kaseta sold 1,091 shares of Liquidia stock. The shares were sold at an average price of $11.51, for a total transaction of $12,557.41.

Liquidia Trading Down 3.4 %

Shares of Liquidia stock opened at $11.36 on Wednesday. The stock has a fifty day simple moving average of $11.20 and a 200 day simple moving average of $11.01. Liquidia Co. has a 12-month low of $8.26 and a 12-month high of $16.99. The company has a market capitalization of $961.48 million, a P/E ratio of -6.97 and a beta of 0.23.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. Lifesci Capital initiated coverage on Liquidia in a research note on Thursday, October 3rd. They issued an “outperform” rating and a $30.00 target price for the company. Wells Fargo & Company began coverage on Liquidia in a report on Friday, December 20th. They set an “overweight” rating and a $20.00 price objective for the company. Needham & Company LLC reiterated a “buy” rating and issued a $19.00 target price on shares of Liquidia in a report on Thursday, January 9th. Scotiabank initiated coverage on shares of Liquidia in a research note on Wednesday, October 16th. They set a “sector outperform” rating and a $30.00 price target for the company. Finally, HC Wainwright restated a “buy” rating and set a $29.00 price objective on shares of Liquidia in a report on Thursday, November 14th. One analyst has rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $25.38.

Institutional Trading of Liquidia

Several institutional investors have recently made changes to their positions in LQDA. BNP Paribas Financial Markets lifted its position in shares of Liquidia by 735.1% during the third quarter. BNP Paribas Financial Markets now owns 140,190 shares of the company’s stock valued at $1,402,000 after purchasing an additional 123,402 shares in the last quarter. Whitefort Capital Management LP increased its stake in Liquidia by 119.8% in the 3rd quarter. Whitefort Capital Management LP now owns 1,702,025 shares of the company’s stock valued at $17,020,000 after buying an additional 927,546 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Liquidia by 144.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 390,257 shares of the company’s stock worth $3,903,000 after buying an additional 230,820 shares in the last quarter. Barclays PLC boosted its stake in shares of Liquidia by 265.0% in the 3rd quarter. Barclays PLC now owns 99,984 shares of the company’s stock worth $999,000 after buying an additional 72,591 shares during the last quarter. Finally, Sapient Capital LLC bought a new position in shares of Liquidia in the third quarter valued at approximately $1,336,000. Institutional investors own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).